secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0001493152-22-012786
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo reports Q3 FY2022 net loss $1.9M; Phase 2 trial fully enrolled
----------------------------------------------------------------------

- Net loss of $1.9M ($0.08/share) for Q3 FY2022 vs $0.6M ($0.68/share) year ago.
- Operating expenses rose to $1.9M from $0.6M in prior year period.
- Cash and cash equivalents totaled $16.5M as of March 31, 2022.
- Completed enrollment of 60 subjects in Part A of Phase 2 trial for ANEB-001; top-line data expected by June 30, 2022.
- Company scheduled to present at four investor conferences and a cannabinoid symposium in May-June 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222012786/0001493152-22-012786-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222012786/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-012786

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer